Home > Publications database > Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. > print

001     168951
005     20251118111811.0
024 7 _ |a 10.1080/2162402X.2021.1920739
|2 doi
024 7 _ |a pmid:34026332
|2 pmid
024 7 _ |a pmc:PMC8128181
|2 pmc
024 7 _ |a 2162-4011
|2 ISSN
024 7 _ |a 2162-402X
|2 ISSN
024 7 _ |a altmetric:106370847
|2 altmetric
037 _ _ |a DKFZ-2021-01153
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zhang, Xin-Wen
|0 P:(DE-He78)0d76712a960555ea778f5b7f35334414
|b 0
|e First author
|u dkfz
245 _ _ |a Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.
260 _ _ |a Abingdon
|c 2021
|b Taylor & Franics
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763461080_1939187
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D170#LA:D170# / #DKFZ-MOST-Ca188#
520 _ _ |a Dendritic cell (DC) vaccination has proven to be an effective and safe adjuvant for cancer immunotherapies. As the presence of DCs within the tumor microenvironment promotes adaptive antitumor immunity, enhancement of DC migration toward the tumor microenvironment following DC vaccination might represent one possible approach to increase its therapeutic efficacy. While recent findings suggest the activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) as critical regulator of DC migration in the context of autoimmune diseases, we aimed to investigate the impact of Arc/Arg3.1 expression for DC-based cancer vaccines. To this end, DC migration capacity as well as the induction of T cell-mediated antitumor immunity was assessed in an experimental B16 melanoma model with Arc/Arg3.1-/- and Arc/Arg3.1-expressing BMDCs applied as a subcutaneous vaccine. While antigen presentation on DCs was critical for unleashing effective T cell mediated antitumor immune responses, Arc/Arg3.1 expression enhanced DC migration toward the tumor and secondary lymphoid organs. Moreover, Arc/Arg3.1-expressing BMDCs shape the tumor immune microenvironment by facilitating tumor recruitment of antigen-specific effector T cells. Thus, Arc/Arg3.1 may represent a novel therapeutic target in DCs in order to increase the therapeutic efficacy of DC vaccination.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Adoptive immunotherapy
|2 Other
650 _ 7 |a CD8-positive T-lymphocytes
|2 Other
650 _ 7 |a dendritic cells
|2 Other
650 _ 7 |a melanoma
|2 Other
650 _ 7 |a tumor microenvironment
|2 Other
700 1 _ |a Huck, Katrin
|0 P:(DE-He78)7ff2c04c9c3a7723806c97a832e47918
|b 1
|u dkfz
700 1 _ |a Jähne, Kristine
|0 P:(DE-He78)106aed16a97ff393cca5528582f8c655
|b 2
|u dkfz
700 1 _ |a Cichon, Frederik
|0 P:(DE-He78)7c69c3cf30a54f9f06e15af48f62ce3c
|b 3
|u dkfz
700 1 _ |a Sonner, Jana
|0 P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b
|b 4
700 1 _ |a Ufer, Friederike
|b 5
700 1 _ |a Bauer, Simone
|b 6
700 1 _ |a Woo, Marcel Seungsu
|b 7
700 1 _ |a Green, Ed
|0 P:(DE-He78)9b97ca569bcb00dfda69382bc7261700
|b 8
|u dkfz
700 1 _ |a Lu, Kevin
|0 P:(DE-He78)88073210769f9ba0da4cf6b7d6c044f8
|b 9
|u dkfz
700 1 _ |a Kilian, Michael
|0 P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc
|b 10
|u dkfz
700 1 _ |a Friese, Manuel A
|b 11
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 12
|u dkfz
700 1 _ |a Sahm, Katharina
|0 P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613
|b 13
|e Last author
|u dkfz
773 _ _ |a 10.1080/2162402X.2021.1920739
|g Vol. 10, no. 1, p. 1920739 -
|0 PERI:(DE-600)2645309-5
|n 1
|p 1920739
|t OncoImmunology
|v 10
|y 2021
|x 2162-402X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168951
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)0d76712a960555ea778f5b7f35334414
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)7ff2c04c9c3a7723806c97a832e47918
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)106aed16a97ff393cca5528582f8c655
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)7c69c3cf30a54f9f06e15af48f62ce3c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)9b97ca569bcb00dfda69382bc7261700
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)88073210769f9ba0da4cf6b7d6c044f8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Tumor immunology
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOIMMUNOLOGY : 2019
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-29
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version)
|0 LIC:(DE-HGF)CCBYNCNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOIMMUNOLOGY : 2019
|d 2021-01-29
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-29
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21